A Phase 4 interventional study of half-dose ticagrelor and standard-dose ticagrelor in Acute Coronary Syndrome, sponsored by First Affiliated Hospital of Harbin Medical University. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-09-12.
Sponsored by First Affiliated Hospital of Harbin Medical University · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 185 studies in Acute Coronary Syndrome with a site in China — 56 open to participants now, 63 under way, 3 of them phase 3. Acute Coronary Syndrome · China.
Among the 185 studies in Acute Coronary Syndrome with a site in China, this one is the 78th largest by planned enrollment of the 115 interventional ones that give a count, is one of 13 that started in 2018, is one of 47 in phase 4, and was the 69th registered.
1,491 studies on the registry are indexed under Acute Coronary Syndrome; 273 are open to participants now.
Browse Acute Coronary Syndrome studies →56 of the 185 studies in Acute Coronary Syndrome with a site in China are open now. Recruiting first, the newest first:
Shenyang Northern Hospital · Sites in China
Ages 18+
Xiling Qi · Sites in China
Ages up to 85
Jilin University · Sites in China
Ages 18–85
Jing Han · Sites in China
Ages 18+
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 196 Acute Coronary Syndrome studies recruiting now, 145 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
185 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 2 · Phase 3 14 · Phase 4 47
First in 2005; this study’s year is marked. 13 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is close to the median of 200 across 868 interventional studies indexed under Acute Coronary Syndrome.
Median enrollment 499 across the 115 interventional studies, 1,312 across the 70 observational. Of the 67 that completed or were terminated, 12 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 185 have an industry lead sponsor. The 10 most frequent:
First Affiliated Hospital of Harbin Medical University is the lead sponsor of 74 studies on the registry; 11 are open to participants now.
First Affiliated Hospital of Harbin Medical University has 3 studies filed under Acute Coronary Syndrome — fewer than ten, so there is no comparison to draw.
18 of the studies in Acute Coronary Syndrome with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06577519Phase 3Jiangsu vcare pharmaceutical technology co., LTDEfficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI) | 2026-12-30 |
| NCT07102628Phase 3Novartis PharmaceuticalsEvaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes | 2027-02-11 |
| NCT05325034Stephen NichollsGuideline Oriented Approach To Lipid Lowering In Asia-Pacific | 2026-12 |
| NCT05638867China National Center for Cardiovascular DiseasesNOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI | 2026-12 |
| NCT05457582Nanjing First Hospital, Nanjing Medical UniversityPCSK 9 Inhibitor Added to High-Intensity Statin Therapy to Prevent Cardiovascular Events in Patients With ACS After PCI | 2026-12-30 |
Add all 18 to your calendar (.ics) → With an account.
Among the 185 studies in Acute Coronary Syndrome with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Dual Antiplatelet Therapy (DAPT) with aspirin and P2Y12 receptor inhibitor remains a cornerstone in the secondary prevention of coronary artery disease (CAD). Clopidogrel is one of the most commonly used antithrombotic agent that inhibits the platelet P2Y(12) adenosine diphosphate (ADP) receptor.
Ticagrelor is an oral, reversibly-binding, direct-acting P2Y12 receptor antagonist used clinically for the prevention of atherothrombotic events in patients with acute coronary syndromes (ACS). Guideline recommendations on the use of dual antiplatelet therapy have been formulated that ticagrelor 90 mg twice daily plus aspirin in preference to clopidogrel 75mg daily plus aspirin for ACS patients. The previous studies have reported that half-dose ticagrelor had the similar inhibitory effect on platelet aggregation as the standard-dose ticagrelor, which was significantly stronger than that in the clopidogrel group. One-quarter standard-dose ticagrelor provided greater degree of platelet inhibition than standard dose clopidogrel in Chinese patients with stable CAD. But the effectiveness and safety of low-dose ticagrelor remain yet not very clearly in Chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: half-dose ticagrelor
Drug: standard-dose ticagrelor
To observe the effectiveness and safety of ticagrelor 45mg bidpo. in Chinese ACS patients undergoing PCI.
To observe the effectiveness and safety of ticagrelor 90mg bidpo. in Chinese ACS patients undergoing PCI.
thromboela-stogram
inhibition of platelet aggregation (ADP) ; MA (ADP)
Time frame: up to 6 months
thromboela-stogram
inhibition of platelet aggregation; MA
Time frame: up to 1 year
MACE
cardiovascular death, non-fatal myocardial infarction and stroke
Time frame: up to 1 year
Side effects including bleeding and dyspnea
Time frame: up to 1 year
The rate of treatment interruption due to ticagrelor intolerance.
Time frame: up to 1 year
Started Jan 2018 (actual). Primary completion is estimated for Dec 2019, 23 months after the start.
Of 85 non-industry phase 4 interventional studies under Acute Coronary Syndrome, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 67. This study's planned 23 months is below that.
Counting every sponsor, half of 92 studies reached it within 42 months; a quarter within 26 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
First Affiliated Hospital of Harbin Medical University